Hutchmed Says Lung Cancer Therapy Improves Progression-Free Survival in China Phase 3 Trial
MT Newswires Live
8 hours ago
Hutchmed (HCM) said Monday its experimental combination of Orpathys and Tagrisso demonstrated a statistically significant improvement in progression-free survival in a China phase 3 trial involving certain patients with non-small cell lung cancer.
The company said the combination also showed encouraging overall survival benefits compared with Tagrisso alone, which was a secondary endpoint of the trial.
Orpathys is jointly developed by AstraZeneca (AZN) and Hutchmed and commercialized by AstraZeneca, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.